BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q2 2022
Top Holdings117 positions
Seattle Genetics Inc | 46.9M | $8.3B | 47.1% | — | — | 8 qtrssince 2020-Q3 | Unchanged 0 |
Incyte Corp | 36.2M | $2.7B | 15.6% | $85.00 | -10.62% | 14 qtrssince 2019-Q1 | Increased 62 |
BEIGENE LTD | 11.7M | $1.9B | 10.7% | $149.70 | +8.12% | 14 qtrssince 2019-Q1 | Unchanged 0 |
BioMarin Pharmaceutical Inc | 7.6M | $631.5M | 3.6% | $88.78 | -5.47% | 14 qtrssince 2019-Q1 | Unchanged 0 |
ACADIA PHARMACEUTICALS INC | 41.9M | $590.7M | 3.4% | $27.57 | -48.90% | 14 qtrssince 2019-Q1 | Increased 58 |
ASCENDIS PHARMA A/S | 4.9M | $451.1M | 2.6% | $125.37 | -24.86% | 14 qtrssince 2019-Q1 | Increased 57 |
ARGENX SE-ADR | 1.1M | $424.2M | 2.4% | $138.29 | +173.98% | 14 qtrssince 2019-Q1 | Unchanged 0 |
BIOCRYST PHARMACEUTICALS INC | 12.7M | $134.5M | 0.8% | $7.50 | +44.22% | 14 qtrssince 2019-Q1 | Unchanged 0 |
KODIAK SCIENCES INC | 17.3M | $132.3M | 0.8% | $34.00 | -77.53% | 14 qtrssince 2019-Q1 | Increased 46 |
Global Blood Therapeutics Inc | 3.7M | $119.3M | 0.7% | — | — | 10 qtrssince 2020-Q1 | Increased 48 |
AbCellera Biologics Inc | 10.5M | $111.3M | 0.6% | $41.10 | -75.40% | 7 qtrssince 2020-Q4 | Unchanged 0 |
Madrigal Pharmaceuticals Inc | 1.5M | $107.3M | 0.6% | $112.39 | -36.31% | 14 qtrssince 2019-Q1 | Unchanged 0 |
Mirati Therapeutics Inc | 1.4M | $94.6M | 0.5% | — | — | 14 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 2.5M | $94M | 0.5% | $43.20 | -16.90% | 6 qtrssince 2021-Q1 | Unchanged 0 |
Horizon Pharma Plc | 1.1M | $91.6M | 0.5% | — | — | 10 qtrssince 2020-Q1 | Increased 52 |
CERUS CORP | 16.1M | $85M | 0.5% | $5.81 | -8.12% | 14 qtrssince 2019-Q1 | Increased 41 |
Retrophin Inc | 3.3M | $80M | 0.5% | $25.43 | -2.94% | 6 qtrssince 2021-Q1 | Unchanged 0 |
REPLIMUNE GROUP INC | 3.6M | $62.8M | 0.4% | $18.83 | -7.35% | 9 qtrssince 2020-Q2 | Increased 57 |
ENTRADA THERAPEUTICS INC | 4.9M | $59.3M | 0.3% | $18.19 | -28.86% | 3 qtrssince 2021-Q4 | Increased 36 |
IGM Biosciences Inc | 3.2M | $56.9M | 0.3% | — | — | 12 qtrssince 2019-Q3 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $17.6B across 117 positions as of Q2 2022. Top holdings: SGEN (47.1%), INCY (15.6%), ONC (10.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
Active quarter - 5 new positions, 6 exits, 24 increased. Top move: INCY (INCREASED, conviction 62). Portfolio: $17.6B across 117 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR